Epidemiology of cancer-associated venous thrombosis

JF Timp, SK Braekkan, HH Versteeg… - Blood, The Journal …, 2013 - ashpublications.org
Cancer-associated venous thrombosis is a common condition, although the reported
incidence varies widely between studies depending on patient population, start and duration …

[HTML][HTML] Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations

BI Bodai, P Tuso - The Permanente Journal, 2015 - ncbi.nlm.nih.gov
Long-term survival rates after a diagnosis of breast cancer are steadily rising. This is good
news, but clinicians must also recognize that this brings new challenges to the medical …

Editor's Choice–European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis

SK Kakkos, M Gohel, N Baekgaard… - European Journal of …, 2021 - ejves.com
2.1. 1. Epidemiology and burden of the disease. The annual incidence of first episode of
symptomatic DVT in the adult population ranges from 50 to 100 per 100 000 population, with …

Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis

S Vedantham, SZ Goldhaber, JA Julian… - … England Journal of …, 2017 - Mass Medical Soc
Background The post-thrombotic syndrome frequently develops in patients with proximal
deep-vein thrombosis despite treatment with anticoagulant therapy. Pharmacomechanical …

Rivaroxaban or aspirin for extended treatment of venous thromboembolism

JI Weitz, AWA Lensing, MH Prins… - … England Journal of …, 2017 - Mass Medical Soc
Background Although many patients with venous thromboembolism require extended
treatment, it is uncertain whether it is better to use full-or lower-intensity anticoagulation …

Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report

C Kearon, EA Akl, J Ornelas, A Blaivas, D Jimenez… - Chest, 2016 - Elsevier
Background We update recommendations on 12 topics that were in the 9th edition of these
guidelines, and address 3 new topics. Methods We generate strong (Grade 1) and weak …

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

Hokusai-VTE Investigators - New England journal of medicine, 2013 - Mass Medical Soc
Background Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin
in patients with venous thromboembolism is unclear. Methods In a randomized, double …

Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice …

C Kearon, EA Akl, AJ Comerota, P Prandoni… - Chest, 2012 - Elsevier
Background This article addresses the treatment of VTE disease. Methods We generated
strong (Grade 1) and weak (Grade 2) recommendations based on high-quality (Grade A) …

The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association

SR Kahn, AJ Comerota, M Cushman, NS Evans… - Circulation, 2014 - Am Heart Assoc
Methods Members of the writing panel were invited by the American Heart Association
Scientific Council leadership because of their multidisciplinary expertise in PTS. Writing …

Oral rivaroxaban for symptomatic venous thromboembolism

Einstein Investigators - New England Journal of Medicine, 2010 - Mass Medical Soc
Background Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose
regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without …